Search results for "Mycose"

showing 10 items of 351 documents

Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period.

2007

Candida guilliermondii fungemia is usually described in adults with hematologic malignancies, but in children, only 2 episodes have been published. From 1995 to 2006, 7 episodes (5 in children) were detected in our hospital. Molecular typing excluded a common infection source. C. guilliermondii fungemia may occur in children with underlying conditions other than cancer.

Microbiology (medical)AdultMalePediatricsmedicine.medical_specialtyGenotypeAdult populationBiologyMolecular typingmedicineHumansCandida guilliermondiiIntensive care medicineChildMycological Typing TechniquesFungemiaMycosisCandidaMolecular EpidemiologyCandidiasisInfant NewbornInfantGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseDNA FingerprintingRandom Amplified Polymorphic DNA TechniqueHospitalizationInfectious DiseasesChild PreschoolFemaleC. guilliermondiiFungemiaDiagnostic microbiology and infectious disease
researchProduct

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

2007

Summary Objectives Invasive fungal infections remain a frequent cause of morbidity and mortality in long-term neutropenic patients. The availability of tolerable broad-spectrum antifungals like voriconazole stimulated the discussion about optimal timing of antifungal therapy. We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML). Methods This was a prospective, randomised, double-blind, placebo-controlled phase III trial in AML patients undergoing remission induction chemotherapy. Oral voriconazole 200mg twice daily or placebo was administered until detection of a lung…

Microbiology (medical)AdultMalePosaconazolemedicine.medical_specialtyAntifungal AgentsAdolescentAdministration OralNeutropeniaPlacebolaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansProspective StudiesAgedVoriconazoleLeukopeniaLung Diseases Fungalbusiness.industryIncidenceInduction chemotherapyLength of StayMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesPyrimidinesMycosesFemaleVoriconazolemedicine.symptombusinessmedicine.drugThe Journal of infection
researchProduct

Outbreak of infection with Klebsiella pneumoniae sequence type 258 producing Klebsiella pneumoniae Carbapenemase 3 in an intensive care unit in Italy

2010

Gram-negative pathogens producing carbapenemases represent an alarming clinical threat with serious effects on patient outcomes ([3][1], [7][2]). In 2001, Yigit et al. ([11][3]) reported a novel β-lactamase termed “ K lebsiella pneumoniae carbapenemase” (KPC-1) in North Carolina. KPC-producing

Microbiology (medical)AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentGenotypeKlebsiella pneumoniaemedicine.medical_treatmentTreatment outcomeMicrobial Sensitivity TestsKlebsiella pneumoniae carbapenem UTI outbreakbeta-Lactamaseslaw.inventionDisease courseMicrobiologyDisease OutbreaksBacterial proteinBacterial Proteinslawpolycyclic compoundsMedicineHumansLetters to the EditorAgedAged 80 and overbiologybusiness.industryOutbreakKlebsiella infectionsSequence Analysis DNAMiddle Agedbacterial infections and mycosesbiology.organism_classificationIntensive care unitDNA FingerprintingAnti-Bacterial AgentsBacterial Typing TechniquesKlebsiella InfectionsIntensive Care UnitsKlebsiella pneumoniaeTreatment OutcomeItalyBeta-lactamaseFemalebusiness
researchProduct

Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.

2008

BACKGROUND: Intensive chemotherapy with severe neutropenia is associated with invasive fungal infections (IFIs) leading to high mortality rates. During leukaemia induction chemotherapy, IFI often prohibited further curative treatment, thus predisposing for leukaemia relapse. Continuing myelosuppressive chemotherapy after diagnosis of IFI has become feasible with the now expanding arsenal of safe and effective antifungals. Secondary prophylaxis of IFI is widely administered, but reliable data on outcome and risk factors for recurrent IFI during subsequent chemotherapy are not available. This study determines risk factors for recurrent IFI in leukaemia patients. METHODS: From 25 European canc…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentNeutropeniaChemopreventionRecurrenceRisk FactorsInternal medicinemedicineHumansPharmacology (medical)Risk factorChildAir filterAgedPharmacologyAged 80 and overbusiness.industryInduction chemotherapyOdds ratioMiddle Agedmedicine.diseaseChemotherapy regimenSurgeryLeukemia Myeloid AcuteInfectious DiseasesLogistic ModelsTreatment OutcomeMycosesChild PreschoolChemoprophylaxisCytarabineFemalebusinessmedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration

2014

Background Anidulafungin is indicated as a first-line treatment for invasive candidiasis in critically ill patients. In the intensive care unit, sepsis is the main cause of acute renal failure, and treatment with continuous renal replacement therapy (CRRT) has increased in recent years. Antimicrobial pharmacokinetics is affected by CRRT, but few studies have addressed the optimal dosage for anidulafungin during CRRT. Patients and methods We included 12 critically ill patients who received continuous venovenous haemodiafiltration to treat acute renal failure. Anidulafungin was infused on 3 consecutive days, starting with a loading dose (200 mg) on Day 1, and doses of 100 mg on Days 2 and 3. …

Microbiology (medical)Antifungal AgentsCritical Illnessmedicine.medical_treatmentHemodiafiltrationAnidulafunginLoading doselaw.inventionSepsisEchinocandinsPharmacokineticslawmedicineHumansCandidiasis InvasivePharmacology (medical)Trough ConcentrationRenal replacement therapyDosingCandidaPharmacologybusiness.industrybacterial infections and mycosesmedicine.diseaseIntensive care unitIntensive Care UnitsInfectious DiseasesAnesthesiaAnidulafunginbusinessmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Antifungal prophylaxis for invasive mycoses in high risk patients.

2006

New broader spectrum antifungal agents with favorable safety profiles have been available for the last 15 years making prophylaxis feasible. The purpose of this article is to review recent studies in patient populations at high risk for invasive fungal infections.Itraconazole, lipid formulations of amphotericin B, posaconazole, caspofungin and micafungin have been utilized for prophylaxis in different immunocompromised host settings. Itraconazole and caspofungin remain an option especially in patients with hematological diseases. Low dose liposomal amphotericin B shows a lower morbidity rate in patients treated for acute myeloid leukemia. Posaconazole demonstrated survival benefits in this …

Microbiology (medical)Antifungalmedicine.medical_specialtyClinical Trials as TopicHigh risk patientsAntifungal Agentsbusiness.industrymedicine.drug_classImmunocompromised HostInfectious DiseasesInvasive MycosesMycosesMedicineHumansIn patientbusinessIntensive care medicineCurrent opinion in infectious diseases
researchProduct

Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric…

2013

ABSTRACT In the absence of clinical breakpoints (CBP), epidemiological cutoff values (ECVs) are useful to separate wild-type (WT) isolates (without mechanisms of resistance) from non-WT isolates (those that can harbor some resistance mechanisms), which is the goal of susceptibility tests. Sensititre YeastOne (SYO) is a widely used method to determine susceptibility of Candida spp. to antifungal agents. The CLSI CBP have been established, but not for the SYO method. The ECVs for four azoles, obtained using MIC distributions determined by the SYO method, were calculated via five methods (three statistical methods and based on the MIC 50 and modal MIC). Respectively, the median ECVs (in mg/lit…

Microbiology (medical)AzolesPosaconazolemedicine.medical_specialtyAntifungal AgentsItraconazoleMycologyMicrobial Sensitivity TestsBiologyMicrobiology:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]EpidemiologymedicineHumansCutoffCandida albicansPruebas de sensibilidad microbianaCandidaVoriconazoleCandidiasisLiter:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Azoles [Medical Subject Headings]:Diseases::Bacterial Infections and Mycoses::Mycoses::Candidiasis [Medical Subject Headings]biology.organism_classification:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antifungal Agents [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Microbiological Techniques::Microbial Sensitivity Tests [Medical Subject Headings]:Organisms::Eukaryota::Fungi::Mitosporic Fungi::Candida [Medical Subject Headings]AntifúngicosFluconazolemedicine.drug
researchProduct

Detection of bacteria and yeast species by the BACTEC 9120 automated system with the routine use of aerobic, anaerobic, and fungal media

2008

ABSTRACT During the period 2006 and 2007, all blood cultures required by four units at high infective risk and most of those required by other units of the University Hospital of Palermo, Palermo, Italy were performed using a Bactec 9120 automated blood culture system with a complete set of Plus Aerobic/F, Plus Anaerobic/F, and Mycosis IC/F bottles. The aim of the study was to enable the authors to gain firsthand experience of the culture potentialities of the three different media, to obtain information regarding the overall and specific recovery of bacteria and yeasts from blood cultures in the hospital, and to reach a decision as to whether and when to utilize anaerobic and fungal bottle…

Microbiology (medical)BacilliSettore MED/07 - Microbiologia E Microbiologia ClinicaAutomated blood cultures Mycosis IC/F Candida albicansMycologyBiologyMicrobiologyAutomationSepsisYeastsmedicineHumansBlood cultureAnaerobiosisCandida albicansMycosisFungemiamedicine.diagnostic_testBacteriaObligate anaerobeBacterial Infectionsmedicine.diseasebiology.organism_classificationAerobiosisCulture MediaBloodItalyMycosesAnaerobic exerciseBacteria
researchProduct

Recurrent bacteraemia by 2 different Bacillus cereus strains related to 2 distinct central venous catheters.

2005

A 14-y-old girl with osteosarcoma developed 3 episodes of catheter-related bacteraemia by Bacillus cereus. After removal of the first and insertion of a second Hickman catheter, further episodes of B. cereus bacteraemia occurred. PFGE analysis revealed that bacteraemic episodes related to each catheter were caused by a distinct B. cereus strain.

Microbiology (medical)Catheterization Central VenousAdolescentBacillus cereusBacteremiaBacillaceae InfectionsMicrobiologyBacillus cereusRecurrencemedicineHumansGeneral Immunology and Microbiologybiologybusiness.industryfungiGeneral Medicinebacterial infections and mycosesbiology.organism_classificationmedicine.diseaseElectrophoresis Gel Pulsed-FieldCatheterInfectious DiseasesCereusBacteremiaHickman catheterbacteriaFemalePfge analysisbusinessScandinavian journal of infectious diseases
researchProduct